title: Cystic Fibrosis Frequently Asked Questions: Question 4: What is the appropriate duration of therapy for respiratory exacerbations in Cystic Fibrosis patients infected with Pseudomonas aeruginosa?
authors.affiliation: Sydney University Medical School, Discipline of Paediatrics and Child Health, University of Sydney.
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Sutton
authors.affiliation: Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia; Sydney Medical School, Discipline of Paediatrics and Child Health, University of Sydney, NSW, Australia. Electronic address: dominic.fitzgerald@health.nsw.gov.au.
authors.forename: Dominic A
authors.initials: DA
authors.lastname: Fitzgerald
mesh_terms: D000280:Administration, Inhalation; D061605:Administration, Intravenous; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents